Vaxcyte said its 31-strain pneumococcal vaccine hit its primary Phase 3 endpoints in a trial against Pfizer's 20-strain and Merck's 21-strain shots. The trial compared antibody levels, so the strain-by-strain results will decide how far the extra coverage threatens the two incumbents.
Perspective Coverage
3 publishers
- Builder
- Builder 30%
- Operator
- Operator 15%
- Investor
- Investor 55%
Reality
- Evidence50
- Adoption3
- Hype gap+30
- Incentives70
- Confidence60
Amino acid solubility sets the ceiling on intensified cell culture, two Pfizer scientists say
In a GEN discussion, Pfizer's Bhanu Chandra Mulukutla and Wenge Wang describe media optimization as a chemistry and plant-operations problem, and the account is practitioners' reasoning.
Reality
- Evidence46
- Adoption30
- Hype gap+12
- Incentives55
- Confidence54
Extended Paxlovid courses failed to beat placebo in a long Covid trial
A Mass General Brigham team stretched a five-day antiviral course to as long as 25 days and tested each ingredient on its own. No clinical benefit appeared, which narrows the viral persistence theory without retiring it.
Reality
- Evidence62
- Adoption
- Not scored
- Hype gap+8
- Incentives28
- Confidence55
The GSK-Pfizer merger did cut costs. A rival put prices up 8.55 percent anyway.
A study of Philippine cough and cold prices confirms real savings on Pfizer lines after the 2019 deal, then finds Sanofi, never a party to it, raised prices by more than Pfizer's fell.
Reality
- Evidence52
- Adoption24
- Hype gap+16
- Incentives58
- Confidence47
CFO turnover heads for 18.3%, and the replacements are four years younger
Crist Kolder projects 18.3% CFO turnover across 665 large-cap companies in 2026, the most since 2020. The more telling number is the average age of the new appointees: 48, down from 52.
Reality
- Evidence52
- Adoption61
- Hype gap+18
- Incentives68
- Confidence56
Amgen drops AMG 513 for MariTide, and the obesity field narrows to a Phase 3 shortlist
The runners-up behind Lilly and Novo are consolidating around a few late-stage assets. Readouts starting next year, not messaging, will decide who takes share.
Reality
- Evidence32
- Adoption24
- Hype gap+22
- Incentives66
- Confidence36
The cell atlas that skipped children, and the $38.5 million effort to fill the gap
A 2017 talk revealed the Human Cell Atlas planned only adult tissue. Pediatric gene expression differs enough that drugs adults tolerate well can kill children.
Reality
- Evidence36
- Adoption30
- Hype gap+14
- Incentives62
- Confidence44
Twenty years of nudges, no movement: the CDC data behind the GLP-1 spending decision
Measured US adult obesity sat at 40.3 percent across 2013 to 2023 while severe obesity rose from 7.7 to 9.7 percent. The programs did not bend the line, and benefits committees now own the question.
Reality
- Evidence66
- Adoption79
- Hype gap+8
- Incentives38
- Confidence54